IMR Press / RCM / Volume 24 / Issue 1 / DOI: 10.31083/j.rcm2401005
Open Access Original Research
Treatment of Moderate Functional Mitral Regurgitation during Aortic Valve Replacement: A Cohort Study
Show Less
1 Department of Cardiovascular Surgery, Fuwai Hospital, National Center for Cardiovascular Diseases, National Clinical Research Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, 10037 Beijing, China
2 Department of Cardiovascular Surgery, Yunnan Fuwai Cardiovascular Hospital, 650000 Kunming, Yunnan, China
*Correspondence: fengwei@fuwai.com (Wei Feng)
These authors contributed equally.
Academic Editors: Takeshi Kitai and Yukikatsu Okada
Rev. Cardiovasc. Med. 2023, 24(1), 5; https://doi.org/10.31083/j.rcm2401005
Submitted: 11 September 2022 | Revised: 14 October 2022 | Accepted: 27 October 2022 | Published: 3 January 2023
(This article belongs to the Special Issue Clinical Updates in Management of Mitral and Tricuspid Valve Disease)
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract

Background: Treatment of moderate functional mitral regurgitation (FMR) during aortic valve replacement (AVR) is controversial. This study aimed to evaluate the effect of different surgical strategies in patients with moderate FMR undergoing AVR. Methods: A total of 468 patients with moderate FMR undergoing AVR from January 2010 to December 2019 were retrospectively studied comparing 3 different surgical strategies, namely isolated AVR, AVR + mitral valve repair (MVr) and AVR + mitral valve replacement (MVR). Survival was estimated using the Kaplan-Meier method and compared with the log-rank test, followed by inverse probability treatment weighting (IPTW) analysis to adjust the between-group imbalances. The primary outcome was overall mortality. Results: Patients underwent isolated AVR (35.3%), AVR + MVr (30.3%), or AVR + MVR (34.4%). The median follow-up was 27.1 months. AVR + MVR was associated with better improvement of FMR during the early and follow-up period compared to isolated AVR and AVR + MVr (p < 0.001). Compared to isolated AVR, AVR + MVR increased the risk of mid-term mortality (hazard ratio [HR]: 2.13, 95% confidence interval [CI]: 1.01–4.48, p = 0.046), which was sustained in the IPTW analysis (HR: 4.15, 95% CI: 1.69–10.15, p = 0.002). In contrast, AVR + MVr showed only a tendency to increase the risk of follow-up mortality (HR: 1.63, 95% CI: 0.72–3.67, p = 0.239), which was more apparent in the IPTW analysis (HR: 2.54, 95% CI: 0.98–6.56, p = 0.054). Conclusions: In patients with severe aortic valve disease and moderate FMR, isolated AVR might be more reasonable than AVR + MVr or AVR + MVR.

Keywords
aortic valve replacement
moderate functional mitral regurgitation
severe aortic valve disease
mitral valve repair
mitral valve replacement
Graphical Abstract
View Full Image
Download
Funding
FZX2019-06-01/Yunnan Provincial Cardiovascular Disease Clinical Medical Center Project of the People’s Republic of China
Figures
Fig. 1.
Share
Back to top